New oral obesity drug matches injectables

infomoney.com.br (Portuguese)

Eli Lilly's new oral obesity drug, orforglipron, shows comparable efficacy to injectable treatments in Phase 3 trials. The Attain-1 study found the oral medication achieved significant weight loss, with the highest dose reducing body weight by up to 12.4% over 72 weeks, similar to injectable semaglutide. The drug also improved cardiovascular health markers and is being further studied for diabetes and sleep apnea, with regulatory submission planned by year-end.


With a significance score of 4.9, this news ranks in the top 1.7% of today's 26329 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


New oral obesity drug matches injectables | News Minimalist